|
Screening for Hematology Branch Protocols Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Screening for Hematology Branch Protocols conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Screening for Hematology Branch Protocols Clinical research trials and Screening for Hematology Branch Protocols healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Screening for Hematology Branch Protocols. Screening for Hematology Branch Protocols Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Screening for Hematology Branch Protocols clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Screening for Hematology Branch Protocols condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Screening for Hematology Branch Protocols  Screening for Hematology Branch Protocols
Screening for Hematology Branch Protocols
For Condition: Anemia,Hematologic Neoplasm,Neutropenia,Pancytopenia,Thrombocytopenia
Status: Recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies. After subjects complete the screening process, they will be offered the opportunity to participate in an active research study, or if no appropriate studies are available information and recommendations will be provided for other treatment options.
Details: This protocol is designed for screening of subjects before a decision can be made as to their eligibility for one of the active Hematology Branch research protocols. Its purpose is to allow detailed investigation into the hematologic or oncologic problems of these subjects, and the status of other organ systems that would determine their ability to safely tolerate specific aspects of active research protocols. It allows investigation as to whether a donor is HLA matched, fit to receive G-CSF, and fit to undergo apheresis and therefore eligible to participate as a donor on a bone marrow transplant protocol. It also allows the investigation as to whether subjects are eligible for participation as normal volunteer based on protocol eligibility criteria that requires generally good health status by history or physical exam findings, or laboratory assessments. After completion of this screening process, the subject will either be offered a chance to participate in an active research protocol, or if no appropriate protocol is identified, subjects with hematologic or oncologic disease will have recommendations for other treatment options relayed to the primary or referring physician.
Eligibility:
Study Type: Observational, Screening
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: ELIGIBILITY ASSESSMENT: INCLUSION CRITERIA: Subjects will be entered on this protocol at the time of their first visit to the NIH Clinical Center outpatient clinic or inpatient service if: The subject carries the diagnosis of a disorder for which the Hematology Branch has an active research protocol, and based on information received from an outside physician, he/she appears to meet at least preliminary eligibility criteria for that protocol. OR The subject is a donor for a subject for which the Hematology Branch has an active stem cell transplant protocol and based on information received from an outside physician, he/she appears to meet preliminary eligibility as a donor. OR The subject is a normal volunteer for which the Hematology Branch has an active study recruiting healthy normal volunteers and he/she appears to meet preliminary eligibility as a normal volunteer. Age greater than or equal to 2 Weight greater than 12 kg The subject or the subject's guardian is capable of informed consent, and willing to sign the consent form after initial counseling by clinical staff. Separate consent forms for all interventional or surgical procedures will be obtained after explanation of the specific procedure.
Total Enrollment: 999999
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 970041; 97-H-0041
Study Start Date: December 6, 1996
Record last reviewed: November 21, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001620
Other Hematologic Neoplasm Studies:
1. Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
2. A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients with Persistent Fever and Neutropenia
3. Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
4. Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
5. Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
Related Studies:
Other Hematologic Neoplasm Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Screening for Hematology Branch Protocols
|
|
|
|
|
|
|
|
